Bernd Hoppe1, Patrick Niaudet2, Rémi Salomon2, Jérôme Harambat3, Sally-Anne Hulton4, William Van't Hoff5, Shabbir H Moochhala6, Georges Deschênes7, Elisabeth Lindner8, Anna Sjögren8, Pierre Cochat9. 1. Department of Pediatrics, Division of Pediatric Nephrology, University Hospital Bonn, Adenauerallee 119, D-53113, Bonn, Germany. bernd.hoppe@ukb.uni-bonn.de. 2. Pediatric Nephrology, Necker Hospital, Université Paris-Descartes, Paris, France. 3. Centre de référence Maladies Rénales Rares du Sud-Ouest, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. 4. Department of Paediatric Nephrology, Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK. 5. Renal Unit, Great Ormond Street Hospital, London, UK. 6. UCL Centre for Nephrology, Royal Free Campus and Hospital, London, UK. 7. Pediatric Nephrology Department, Robert Debré Hospital, Paris, France. 8. OxThera AB, Stockholm, Sweden. 9. Centre de référence des Maladies Rénales Rares, Hôpital Femme Mère Enfant, Bron, France.
Abstract
BACKGROUND: Primary hyperoxaluria (PH) is a rare, genetic disorder which involves the overproduction of endogenous oxalate, leading to hyperoxaluria, recurrent urolithiasis and/or progressive nephrocalcinosis and eventually resulting in kidney failure and systemic oxalosis. The aim of this trial was to investigate whether treatment involving an oxalate-metabolising bacterium (Oxalobacter formigenes) could reduce urinary oxalate excretion in PH patients. METHODS: The efficacy and safety of O. formigenes (Oxabact® OC5; OxThera AB, Stockholm, Sweden) was evaluated in a randomised, placebo-controlled, double-blind study for 8 weeks. The primary objective was reduction in urinary oxalate excretion (Uox). Secondary objectives included faecal O. formigenes count and decrease in plasma oxalate concentration (Pox). RESULTS: Twenty-eight patients randomised 1:1 to the treatment group (OC5) or the placebo group completed the study. After 8 weeks of treatment, there was no significant difference in the change in Uox (mmol/24 h/1.73 m2) between the groups (OC5: +0.042, placebo: -0.140). Post-hoc analysis showed a statistically significant increase in Uox per urinary creatinine excretion in the OC5 group (OC5: +5.41, placebo: -15.96; p = 0.030). Change in Pox from baseline was not significantly different between groups (p = 0.438). The O. formigenes cell count was significantly increased in OC5-treated patients (p < 0.001) versus placebo. The treatment response to O. formigenes was related to individual stage of kidney deterioration, and Pox was directly correlated to kidney function, even for early-stage patients (chronic kidney disease stage 1). No safety issues were observed. CONCLUSIONS: Treatment with OC5 did not significantly reduce Uox or Pox over 8 weeks of treatment. The treatment was well tolerated and successfully delivered to the gastrointestinal tract.
RCT Entities:
BACKGROUND:Primary hyperoxaluria (PH) is a rare, genetic disorder which involves the overproduction of endogenous oxalate, leading to hyperoxaluria, recurrent urolithiasis and/or progressive nephrocalcinosis and eventually resulting in kidney failure and systemic oxalosis. The aim of this trial was to investigate whether treatment involving an oxalate-metabolising bacterium (Oxalobacter formigenes) could reduce urinary oxalate excretion in PH patients. METHODS: The efficacy and safety of O. formigenes (Oxabact® OC5; OxThera AB, Stockholm, Sweden) was evaluated in a randomised, placebo-controlled, double-blind study for 8 weeks. The primary objective was reduction in urinary oxalate excretion (Uox). Secondary objectives included faecal O. formigenes count and decrease in plasma oxalate concentration (Pox). RESULTS: Twenty-eight patients randomised 1:1 to the treatment group (OC5) or the placebo group completed the study. After 8 weeks of treatment, there was no significant difference in the change in Uox (mmol/24 h/1.73 m2) between the groups (OC5: +0.042, placebo: -0.140). Post-hoc analysis showed a statistically significant increase in Uox per urinary creatinine excretion in the OC5 group (OC5: +5.41, placebo: -15.96; p = 0.030). Change in Pox from baseline was not significantly different between groups (p = 0.438). The O. formigenes cell count was significantly increased in OC5-treated patients (p < 0.001) versus placebo. The treatment response to O. formigenes was related to individual stage of kidney deterioration, and Pox was directly correlated to kidney function, even for early-stage patients (chronic kidney disease stage 1). No safety issues were observed. CONCLUSIONS: Treatment with OC5 did not significantly reduce Uox or Pox over 8 weeks of treatment. The treatment was well tolerated and successfully delivered to the gastrointestinal tract.
Authors: John C Lieske; Carla G Monico; W Scott Holmes; Erik J Bergstralh; Jeffrey M Slezak; Audrey L Rohlinger; Julie B Olson; Dawn S Milliner Journal: Am J Nephrol Date: 2005-06-15 Impact factor: 3.754
Authors: Bernd Hoppe; Jaap W Groothoff; Sally-Anne Hulton; Pierre Cochat; Patrick Niaudet; Markus J Kemper; George Deschênes; Robert Unwin; Dawn Milliner Journal: Nephrol Dial Transplant Date: 2011-04-02 Impact factor: 5.992
Authors: Judith Parsells Kelly; Gary C Curhan; David R Cave; Theresa E Anderson; David W Kaufman Journal: J Endourol Date: 2011-03-07 Impact factor: 2.942
Authors: Christiaan S van Woerden; Jaap W Groothoff; Ronald J A Wanders; Jean-Claude Davin; Frits A Wijburg Journal: Nephrol Dial Transplant Date: 2003-02 Impact factor: 5.992
Authors: Aaron W Miller; Kristina L Penniston; Kate Fitzpatrick; José Agudelo; Gregory Tasian; Dirk Lange Journal: Nat Rev Urol Date: 2022-09-20 Impact factor: 16.430
Authors: Patrice D Cani; Clara Depommier; Muriel Derrien; Amandine Everard; Willem M de Vos Journal: Nat Rev Gastroenterol Hepatol Date: 2022-05-31 Impact factor: 73.082
Authors: Dawn S Milliner; Pierre Cochat; Sally-Anne Hulton; Jerome Harambat; Ana Banos; Bastian Dehmel; Elisabeth Lindner Journal: Pediatr Nephrol Date: 2021-01-30 Impact factor: 3.714
Authors: Steven L Daniel; Luke Moradi; Henry Paiste; Kyle D Wood; Dean G Assimos; Ross P Holmes; Lama Nazzal; Marguerite Hatch; John Knight Journal: Appl Environ Microbiol Date: 2021-08-26 Impact factor: 4.792